Drug Resistant Epilepsy clinical trials

Explore recruiting drug resistant epilepsy clinical trials.

Recruiting drug resistant epilepsy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Drug Resistant Epilepsy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Impact of epilepsy on the brainstem adenosine pathway and its relation with arousal and respiratory reactivity BRAVE

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, multiple ascending doses, clinical trial to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of CV-01 after double-blind, placebo-controlled multiple oral administrations for 2 weeks in healthy volunteers, and multiple oral administrations open-label for 2 weeks in a cohort of participants with drug resistant epilepsy

Sweden

Human Pharmacology (Phase I)- Other EU CTIS Study details

Add-on Clioquinol in drug-resistant epilepsy: an exploratory study

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Open, randomized, IInd phase clinical study evaluating the safety and efficacy of rapamycin in the treatment of drug-resistant epilepsy in children with rare and ultra rare diseases of the central nervous system associated with the activation of the mTOR pathway : BraimTOR-NEURO

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Multicenter, randomized, double-blind, placebo controlled study to assess the efficacy and safety of RApamycin in drug Resistant Epilepsy associated with TSC

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomized, placebo-controlled, double-blind and double-dummy clinical trial comparing the safety, tolerability, and efficacy of vigabatrin and rapamycin in a preventive treatment of infants with Tuberous Sclerosis Complex

Poland

Phase II and Phase III (Integrated) EU CTIS Study details

Drug Resistant Epilepsy trials by city

Drug Resistant Epilepsy in Toronto Drug Resistant Epilepsy in Vancouver Drug Resistant Epilepsy in Montreal Drug Resistant Epilepsy in Calgary Drug Resistant Epilepsy in Edmonton Drug Resistant Epilepsy in Ottawa Drug Resistant Epilepsy in Winnipeg Drug Resistant Epilepsy in Quebec City Drug Resistant Epilepsy in Hamilton Drug Resistant Epilepsy in Kitchener Drug Resistant Epilepsy in London Drug Resistant Epilepsy in Halifax Drug Resistant Epilepsy in New York Drug Resistant Epilepsy in Los Angeles Drug Resistant Epilepsy in Chicago Drug Resistant Epilepsy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease